Australia appears to be gain access to potentially transformative treatment for obesity: Retatrutide. This dual compound – acting on both GLP-1 and GIP receptors – demonstrates promising outcomes in international research, suggesting meaningful decreases in body fat. While approval remains with Australian regulators, many Australians struggling